...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data
【24h】

Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data

机译：囊性纤维化患者对妥布霉素吸入粉末与吸入溶液的依从性：美国保险理赔数据分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Tobramycin inhalation powder (TIP), the first dry-powder inhaled antibiotic for pulmonary Pseudomonas aeruginosa infection, is associated with reduced treatment burden, increased patient satisfaction, and higher self-reported adherence for cystic fibrosis (CF) patients. We compared adherence in CF patients newly treated with TIP with those newly treated with the traditional tobramycin inhalation solution (TIS), using US insurance claims data. Patients and methods: From the Truven MarketScan? database, we identified CF patients chronically infected with P. aeruginosa who had been prescribed TIP between May 1, 2013 to December 31, 2014, or TIS between September 1, 2010 to April 30, 2012 with at least 12 months of continuous medical and pharmacy benefits prior to and following prescription. TIP and TIS adherence levels were assessed. Results: A total of 145 eligible patients were identified for the TIP cohort and 306 for the TIS cohort. Significant differences in age distribution (25.0 vs 21.9 years for TIP vs TIS, respectively, P =0.017), type of health plan ( P =0.014), employment status (72.4% vs 63.4% of TIP vs TIS patients in full-time employment, P =0.008), and some comorbidities were observed between the two cohorts. Although a univariate analysis found no significant differences between TIP and TIS (odds ratio [OR] 1.411, 95% confidence interval [CI] 0.949–2.098), TIP was moderately associated with higher adherence levels compared with TIS in a multivariable analysis, once various demographic and clinical characteristics were adjusted for. These included geographic location (OR: 1.566, CI: 1.016–2.413) and certain comorbidities. Conclusion: This study of US patient data supports previous findings that TIP is associated with better adherence compared with TIS; however, further studies will be required to fully elucidate differences in adherence between TIP and TIS.
机译：目的：妥布霉素吸入粉末（TIP）是用于治疗肺铜绿假单胞菌感染的首种干粉吸入抗生素，与减轻治疗负担，增加患者满意度以及对囊性纤维化（CF）患者的自我报告依从性更高相关。我们使用美国保险理赔数据，将接受TIP新治疗的CF患者与接受传统妥布霉素吸入溶液（TIS）新治疗的CF患者的依从性进行了比较。患者和方法：从Truven MarketScan ？数据库中，我们确定了慢性感染铜绿假单胞菌的CF患者，这些患者在2013年5月1日至2014年12月31日期间开了TIP，或在9月1日之间开了TIS 2010年至2012年4月30日，处方前后至少连续12个月提供医疗和药学福利。评估了TIP和TIS的依从性水平。结果：总共145例TIP队列和306例TIS队列符合条件的患者。 TIP与TIS患者的年龄分布（分别为25.0和21.9岁，分别为TIP与TIS，P = 0.017），健康计划类型（P = 0.014），就业状况（分别为TIP与TIS患者的72.4％vs 63.4％）存在显着差异，P = 0.008），并且在两个队列之间观察到一些合并症。尽管单变量分析发现TIP和TIS之间没有显着差异（优势比[OR] 1.411，95％置信区间[CI] 0.949–2.098），但在多变量分析中，与TIS相比，TIP与中等依从性较高相关人口统计学和临床​​特征进行了调整。其中包括地理位置（OR：1.566，CI：1.016–2.413）和某些合并症。结论：这项对美国患者数据的研究支持了先前的发现，即与TIS相比，TIP与更好的依从性相关。但是，将需要进一步研究以完全阐明TIP和TIS之间依从性的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号